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Vitamin D deficiency is associated with higher cardio-
vascular risk and metabolic syndrome (MeS) criteria. 
The main objective of this study was to analyse the 
association of 25-hydroxyvitamin D (25-OHD) serum 
levels with MeS (National Cholesterol Education Pro-
gram–Adult Treatment Panel-III criteria) in 46 Spa-
nish patients with psoriasis, but without arthritis and 
systemic treatment, and 46 control subjects, matched 
by sex and age. The patients with psoriasis showed sig-
nificantly lower level of 25-OHD than controls (30.5 vs. 
38.3 ng/ml; p = 0.0001). Patients with MeS had signifi-
cantly lower serum levels of 25-OHD than those wit-
hout MeS (24.1 ± 7.5 vs. 32.8 ± 8.9, p = 0.007), and a nega-
tive correlation was found between 25-OHD and waist 
circumference, diastolic blood pressure, fasting glucose, 
and triglyceridaemia. In the control group no signifi-
cant correlation between 25-OHD and MeS was found. 
Al though the sample was small, our results suggest a 
potential protective role for 25-OHD in the metabolic 
profile of patients with psoriasis without arthritis. Key 
words: psoriasis; vitamin D; metabolic syndrome; cardio-
vascular risk. 
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Vitamin D has classically been associated with phospho-
rus-calcium metabolism and bone physiology. However, 
the finding of vitamin D receptors at different sites (1) 
suggests that vitamin D also has important extraskeletal 
functions. Thus, low levels of vitamin D have been as-
sociated with adverse cardiovascular outcomes (2, 3) and 
metabolic syndrome (MeS). Individuals meeting Adult 
Treatment Panel (ATP-III) criteria for MeS have been 
found to have a greater likelihood of a cardiovascular 
event over the following 10 years (4).
Psoriasis has been associated with a higher prevalence 
of MeS and an increase in cardiovascular events (5–7), 
as also observed for other inflammatory dermatological 
diseases (8).
Several studies have reported vitamin D deficiency 
in patients with autoimmune diseases (9) as well as in 
psoriatic patients (10, 11).
Given the scarcity of published data relating vitamin D 
status and MeS in psoriasis, we conducted a case-control 
study in order to evaluate the association of serum 25-hy-
droxyvitamin D (25-OHD) levels with the presence of 
MeS and metabolic parameters in patients with psoriasis.
METHODS
Psoriatic patients
Patients with active psoriasis were systematically recruited 
from the outpatient clinic of the Dermatology Department of 
San Cecilio University Hospital (Granada, Spain). Inclusion 
criteria were: a clinical diagnosis of psoriasis, age ≥ 18 years, 
and residence in the metropolitan area of Granada. Exclusion 
criteria were: “sunny” holidays in the previous month, intake 
of calcium or vitamin D supplements in the previous 3 months, 
psoriatic arthritis (Classification Criteria for Psoriatic Arthritis 
criteria), psoriasis systemic treatment in the previous 6 months, 
antihypertensive, lipid-lowering, or antidiabetic therapy in the 
previous 3 months, or medical history of rheumatoid arthritis, 
type 1 diabetes mellitus, inflammatory bowel disease, multiple 
sclerosis, or renal function impairment. 
Control individuals
Control individuals from the same geographical area were re-
cruited from the dermatology outpatient clinic (mainly naevi, 
seborrhoeic keratosis, or verruca) matched with psoriasis 
patients by sex and age (± 2 years). Individuals were recruited 
with a time difference less than 7 days since their matched pso-
riatic patient was evaluated. Exclusion criteria were the same 
as established for the psoriatic patients group. All patients or 
controls were recruited between 18 July and 30 August 2011 to 
avoid bias due to seasonal variations in vitamin D.
The study was approved by the ethics committee of San Cecilio 
University Hospital, and written informed consent was obtained 
from all patients in accordance with the Helsinki Declaration.
Clinical and laboratory parameters
Data were gathered on: age, sex, family history of psoriasis 
and age at diagnosis. We also recorded current tobacco habit 
(pack-years), alcohol intake (g/week), and an estimation of the 
time spent in the open air over the previous 4 weeks. Patients 
were asked about their consumption of vitamin D-rich and 
fortified foods in their usual diet, including: salmon, sardine, 
tuna, egg-yolk, and vitamin-D fortified butter, margarine, milk, 
yoghurt, cheese, and breakfast cereals (12). These data were 
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used to calculate their daily vitamin D intake (in international 
units; IU). Physical activity was assessed as the usual level of 
exercise over the previous year by means of the Tromsø physical 
activity questionnaire, which has proven to be a good predictor 
of heart rate at rest and physical condition, comparable to the 
objective assessment of activity by accelerometry (13).
Participants’ waist circumference, weight and height were 
recorded and their body mass index (BMI; kg/m2) calculated. 
Fitzpatrick phototype was also evaluated. Systolic (SBP) and 
diastolic (DBP) blood pressures were measured after a 5-min rest, 
and again after a 10-min interval, and the mean values were recor-
ded. Moreover, in psoriatic patients Psoriasis Area and Severity 
Index (PASI), and body surface area (BSA) were also registered.
blood samples were drawn between 08.00 h and 09.00 h for 
laboratory analysis of biochemical parameters (triglycerides 
(TG), total cholesterol (TC), low density lipoprotein (lDl), 
high density lipoprotein (HDl), and fasting glucose), intact pa-
rathyroid hormone (iPTH), serum calcium, serum phosphorus, 
serum creatinine, and determination of serum 25-(OH)D levels 
by radioimmunoassay. Prevalence of the MeS was calculated 
according to national Cholesterol education Program-Adult 
Treatment Panel (nCeP-ATP-III) criteria (14). 
Statistical analysis
After descriptive statistical analysis of the general characte-
ristics of the study participants, the Kolmogorov–Smirnov 
test was used to examine the distribution of variables, and the 
levene test to study the variance. Student’s t-test was applied 
to compare mean values of quantitative variables when the 
distribution was normal and the Mann–Whitney U test when 
it was not. Qualitative variables were analysed with the χ2 test 
or with Fisher’s exact test if at least one cell had an expected 
count < 5. For paired samples the Student’s t-test for paired 
samples and Mcnemar test were used. Pearson’s coefficient 
was used to test the correlation between quantitative variables 
and serum 25-(OH)D level. Binary logistic regression models 
(Wald method) were used to measure the association between 
the presence of MeS and vitamin D levels in a multivariate 
analysis. p ≤ 0.05 was considered significant. SPSS 17.0 was 
used for data analyses (SPSS Inc., Chicago, Il, USA).
rESUlTS
This study includes 92 individuals, 46 psoriatic patients 
without arthritis who were receiving no systemic treat-
ment for psoriasis or any anti-diabetic, anti-hypertensi-
ve, or lipid-lowering therapy, and 46 healthy controls. 
Table I summarizes data on the MeS parameters and 
the confounding factors associated with vitamin D sta-
tus. Patients with psoriasis presented lower significant 





n = 46 p-value
Age, years, mean ± SD 45.57 ± 9.96 45.89 ± 10.06 0.876
Sex, male, % 26 (56.5) 26 (56.5) 1.000 
PASI, mean ± SD 4.28 ± 4.38 – –
body surface area, %, mean ± SD 5.10 ± 7.08 – –
Time with psoriasis, years, mean ± SD 18.58 ± 11.81 – –
Family history of psoriasis, n (%) 20 (43.5) – –
Fitzpatrick skin phototype
  I–III, %






Waist circumference, cm, mean ± SD 97.57 ± 10.74 94.58 ± 11.75 0.207
Body mass index, kg/m2, mean ± SD 28.50 ± 5.44 26.84 ± 3.80 0.093
Smoking, pack-years, mean ± SD 11.97 ± 12 9.85 ± 12.28 0.405 
Alcoholism, g/week, mean ± SD 89.83 ± 135.41 71.54 ± 92.56 0.452 
Physical activity, level 1 (%) 17 (37.0) 19 (41.3) 0.669 
Vitamin D intake, IU/day, mean ± SD 188.72 ± 136.83 172.92 ± 102.18 0.532
Sun exposure h/week, mean ± SD 25.98 ± 16.42 23.87 ± 17.14 0.548
Systolic blood pressures, mmHg, mean ± SD 132.52 ± 16.76 126.07 ± 25.95 0.288
Diastolic blood pressures, mmHg, mean ± SD 81.76 ± 10.28 76.30 ± 16.07 0.095
Fasting glucose, mg/dl, mean ± SD 102.09 ± 45.21 86.46 ± 9.36 0.026
Total-C, mg/dl, mean ± SD 207.57 ± 37.05 201.54 ± 38.85 0.452 
lDl-C, mg/dl, mean ± SD 129.57 ± 31.04 125.85 ± 35.22 0.593
HDl-C; mg/dl, mean ± SD 52.52 ± 14.38 54.54 ± 13.36 0.487
TG, mg/dl, mean ± SD 140.74 ± 91.64 103.61 ± 47.46 0.017
Metabolic syndrome, n (%) 14 (30.4) 8 (17.4) 0.143 
Calcium, mg/dl, mean ± SD 9.34 ± 0.40 9.34 ± 0.44 0.964
Phosphorus, mg/dl mean ± SD 3.25 ± 0.54 3.11 ± 0.55 0.184
Intact parathyroid hormone, pg/ml, mean ± SD 41.90 ± 14.70 39.80 ± 14.05 0.402
Creatinine, mg/dl, mean ± SD 0.75 ± 0.13 0.76 ± 0.13 0.783
25-hydroxyvitamin D, ng/ml, mean ± SD
  < 20 ng/ml (%) 
     20–< 25 ng/ml (%)
     25–< 30 ng/ml (%) 
     30–< 40 ng/ml (%) 
  > 40 ng/ml (%)
30.52 ± 9.29
  9 (19.6)
  7 (15.2)
  9 (19.6)
14 (30.4)
  7 (15.2)
38.31 ± 9.56
  0 (0)
  0 (0)




SD: standard deviation; PASI: Psoriasis Area and Severity Index; IU: International Units; Total-C: total cholesterol; lDl-C: low-density lipoprotein cholesterol; 
HDl-C: high-density lipoprotein cholesterol; TG: triglycerides.
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25-OHD levels than controls (30.5 ± 9.3 vs. 38.3 ± 9.6 
ng/ml; p = 0.0001); 54.4% vs. 22.6% in the control 
group (p < 0.0001) evidenced vitamin D insufficiency 
(< 30 ng/ml). A higher proportion of individuals met 
MeS criteria in the psoriatic group (30.4% vs. 17.4% in 
control group) (p = 0.143), and the patients had increased 
fasting glucose (102.1 vs. 86.5 mg/dl, p = 0.026) and TG 
(140.7 vs. 103.6 mg/dl, p = 0.017) levels. 
In psoriatic patients, 25-OHD serum levels were ne-
gatively associated with age (r = –0.477, p = 0.001), BMI 
(r = –0.410, p = 0.005), waist circumference (r = –0.454, 
p = 0.002), alcohol intake (r = –0.305, p = 0.039), DBP 
(r = –0.320, p = 0.030), fasting glucose (r = –0.329, 
p = 0.026), and serum TG (r = –0.368, p = 0.012) (Fig. 
S11). A trend to signification correlation was found 
between 25-OHD level and SBP (r = –0.287; p = 0.053), 
sun exposure (r = 0.266; p = 0.074), and daily vitamin D 
intake (r = 0.257; p = 0.085). no significant correlation 
was found between psoriasis-related variables (PASI, 
bSA, family history of psoriasis and “time with pso-
riasis”) and 25-OHD levels2. 
In the control group, a positive correlation was found 
between 25-OHD levels and sun exposure (r = 0.427, 
p = 0.003) and between 25-OHD levels and HDl-c 
levels (r = 0.286, p = 0.054). 
both groups were divided regarding the presence of 
MeS (Table SI1). In the psoriasis group, the mean se-
rum 25-OHD level was significantly lower in patients 
with MeS (24.1 ± 7.5 vs. 32.8 ± 8.9, p = 0.007). In the 
control group no significant differences were found in 
25-OHD levels among individuals with and without 
MeS. Patients with psoriasis and MeS presented ne-
arly significant higher values of PASI (3.61 vs. 6.18, 
p = 0.08). Also, patients and controls with MeS showed 
higher significant BMI than patients or controls without 
MeS. no significant differences were found in age, 
sex, smoking status, alcohol intake, physical activity, 
sun exposure, or daily vitamin D intake in patients or 
controls regarding the presence of metabolic syndrome. 
The binary logistic regression model for MeS in pso-
riatic patients showed a positive significant association 
with 25-OHD insufficiency (p = 0.038) after controlling 
for age, BMI, alcohol intake, sun exposure, vitamin D 
intake and physical activity (Table II).
DISCUSSIOn
In this study serum 25-OHD levels were significantly 
lower in patients with psoriasis than in controls. Mo-
reover, in the psoriatic group serum 25-OHD levels 
were significantly and inversely correlated with some 
MeS criteria, i.e. waist circumference, DbP, fasting 
glucose and TG levels. Thus, psoriatic patients with 
MeS showed a significantly lower level of 25-OHD than 
patients without MeS. low levels of 25-OHD in pso-
riatic patients have been described previously (10, 11).
Waist circumference and BMI (proxies for adiposity) 
were previously reported to be negatively associated 
with vitamin D in general and psoriatic populations 
(10, 15). This relationship can be partially explained 
by the liposolubility of vitamin D and its reduced 
bioavailability in bodies with a high fat content (15), 
although a significant negative association between 
MeS and vitamin D independent of adiposity was ob-
served in a study of morbidly obese patients (16). In 
our study the association between 25-OHD and MeS 
persisted after binary logistic regression that included 
the BMI. regarding the lower level of vitamin D in 
obese subjects, a lower level of exposure to the sun 
has been suggested due to poor mobility or cosmetic 
concerns3. In addition to the possible reduction in vi-
tamin D biodisponibility in obese subjects, it has been 
suggested that vitamin D could regulate adipogenesis, 
and that pre-adipocyte differentiation inhibition is 
mediated via the vitamin D receptor-dependent inhibi-
tion of C/eBPα and peroxi some proliferator-activated 
receptor γ expression (17).
regarding other MeS criteria, all have shown an 
inverse correlation with 25-OHD levels in epidemio-
logical or experimental studies supporting these as-
sociations. Vitamin D receptors are present in human 1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1642 
2In the psoriasis group, serum 25-OHD levels were calculated according to 
the presence of nCeP-ATP III criteria and were significantly lower in patients 
with higher waist circumference (≤ 102 cm vs. > 102 cm: 34.30 ± 8.71 vs. 
26.39 ± 8.22 ng/ml, p = 0.004), higher fasting glucose (< 100 mg/dl vs. ≥ 100 
mg/dl: 32.55 ± 9.10 vs. 24.05 ± 6.80 ng/ml, p = 0.007), and higher TG (< 150 
mg/dl vs. ≥ 150 mg/dl: 32.49 ± 8.69 vs. 26.45 ± 9.44 ng/ml, p = 0.024), and 
a trend to signification was found for DBP (< 85 mmHg vs. ≥ 85 mmHg: 
32.91 ± 9.29 vs. 27.67 ± 8.66, p = 0.085). no significant differences in 25-
OHD serum levels were found as a function of the presence of systolic 
hypertension or low HDl-C levels.
3However, we controlled this potential confounding factor in the present 
study by various means: exclusively enrolling residents of the same locality 
(Granada metropolitan area, Southern Spain); excluding patients who had 
been on a sunny holiday in the previous month; performing the study within 
a narrow time-interval; and obtaining a self-estimate of sun exposure during 
the previous month. Moreover, no significant differences in sun exposure were 
found between obese and non-obese patients (data not shown).
Table II. Binary logistic regression model for metabolic syndrome 
(MeS) (NCEP-ATP III) in psoriatic patients. 25-hydroxyvitamin 
D (25-OHD) shows an independent association with MeS after 
adjusting for potential confounding factors
Variable Odds ratio 95% confidence interval p-value
Age 0.948 0.853–1.053 0.317
body mass index 1.080 0.926–1.259 0.328
Alcohol intake 0.999 0.993–1.005 0.825
Sun exposure 1.000 0.960–1.042 1.000
Vitamin D intake 1.003 0.996–1.010 0.429
Physical activity 1.260 0.243–6.534 0.783
25-OHD insufficiency 0.844 0.720–0.990 0.038
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cells that can contribute to modifying blood pressure 
(e.g. cardiomyocytes, vascular smooth muscle cells, 
endothelial cells, and renin-producing juxtaglomerular 
cells) (18, 19). experimental studies have reported a 
regulative role for vitamin D in the renin system (19, 
20). Moreover, vitamin D supplementation has been 
reported to have a beneficial effect on blood pressure in 
humans (21) and rats (22). A role for vitamin D in glu-
cose metabolism is supported by the presence of vitamin 
D receptors (23) and the 1α-hydroxylase enzyme (24) 
in β pancreatic cells, and by experimental findings of 
increased glucose-mediated insulin secretion in animals 
after vitamin D administration (25). The present finding 
of an inverse association between serum 25-OHD and 
TG values is also in agreement with cross-sectional or 
longitudinal studies (26, 27). Moreover, pro-inflamma-
tory cytokines related with lipolysis (increase in free 
fatty acids) and insulin-resistance can be regulated by 
vitamin D (28, 29). Although in our sample significant 
correlation between vitamin D and HDl-c has not been 
found, a significant direct correlation has been found in 
other studies. It could be explained by the direct rela-
tionship found between vitamin D and apolipoprotein 
A-I, the main component of HDl-c. However, intrinsic 
mechanism is unknown (30). See Fig. S21) for an inte-
grated view of potential interrelations between different 
components of MeS and 25-OHD. 
Currently, the intrinsic mechanisms that regulate the 
extraskeletal functions of vitamin D are not well known. 
In the study by Oh et al. (31), macrophages from a group 
of patients (obese, diabetic, hypertensive patients with 
vitamin D deficiency) showed a significant suppres-
sion of foam cell formation by reducing acetylated or 
oxidized low-density lipoprotein cholesterol uptake 
when were cultured in a media with 1,25-(OH)2D vs. 
macrophages cultured in a vitamin D-deficient media. 
However, this significant effect was not observed in 
a control group (obese, non-diabetic, hypertensive 
patients with vitamin D deficiency). In this sense, dif-
ferences in correlation between MeS parameters and 
vitamin D have been found in our study in psoriasis 
group vs. control group. 
There are few studies evaluating the benefit of vita-
min D supplementation on metabolic parameters. In the 
study of Al-Daghri et al. (32) a small benefit in terms 
of the cholesterol profile was found after one year of 
vitamin D supplementation in a general population. Mo-
reover, different benefits of vitamin D supplementation 
have been reported, depending on population features; a 
greater benefit seems to exist in patients receiving dia-
lysis than in the general population (33). Thus, based on 
differences found in correlation of 25-OHD-metabolic 
parameters among the psoriasis group and the control 
group in the present study, it might be hypothesized that 
a greater benefit could result from vitamin D supple-
mentation in a psoriasis population. 
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